A5034342116- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Colorectal Cancer Treatments and Studies
- Neuroendocrine Tumor Research Advances
- Esophageal Cancer Research and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- Cancer Research and Treatments
- Cancer therapeutics and mechanisms
- Hepatocellular Carcinoma Treatment and Prognosis
- CAR-T cell therapy research
- Cancer Cells and Metastasis
- Genetic factors in colorectal cancer
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Gut microbiota and health
- Glycosylation and Glycoproteins Research
- Renal cell carcinoma treatment
- Colorectal and Anal Carcinomas
- Neuroblastoma Research and Treatments
China Agricultural University
2025
Peking University Cancer Hospital
2015-2024
University of Electronic Science and Technology of China
2024
Peking University
2015-2024
Qingdao University
2019-2024
Lanzhou University
2024
Dazhou Central Hospital
2021-2024
Sichuan University
2024
Affiliated Hospital of Qingdao University
2024
Shandong University
2024
Abstract Despite success in hematologic malignancies, the treatment landscape of chimeric antigen receptor (CAR) T cell therapy for solid tumors remains limited. Claudin18.2 (CLDN18.2)-redirected CAR cells showed promising efficacy against gastric cancer (GC) a preclinical study. Here we report interim analysis results an ongoing, open-label, single-arm, phase 1 clinical trial CLDN18.2-targeted (CT041) patients with previously treated, CLDN18.2-positive digestive system cancers ( NCT03874897...
We report on a comprehensive analysis of the gut microbiomes patients with gastrointestinal (GI) cancer receiving anti-PD-1/PD-L1 treatment. The human microbiota has been associated clinical responses to immunotherapy in melanoma, non-small cell lung cancer, and renal carcinoma. aimed investigate this association GI cancers. also identified bacterial taxa patient stratification potential. recruited 74 advanced-stage treatment collected their fecal samples prior during immunotherapy, along...
Abstract Purpose RC48 contains the novel humanized anti-HER2 antibody hertuzumab conjugated to MMAE via a cleavable linker. A phase I study was initiated evaluate toxicity, MTD, PK, and antitumor activity of in patients with HER2-overexpressing locally advanced or metastatic solid carcinomas, particularly gastric cancer. Patients methods This 2-part study. Successive cohorts received escalating doses (0.1 mg/kg, 0.5 1.0 2.0 2.5 3.0 mg/kg). Dose expansion proceeded at dose mg/kg Q2W. The...
Although the antibody-drug conjugates (ADCs) have significantly improved survival outcomes of patients with human epidermal receptor 2 (HER2)-expressing gastric or gastroesophageal junction (G/GEJ) cancer, efficacy ADC used as a single agent is limited. Therefore, it necessary to investigate effective and safe combination regimens. Preclinical data indicated synergetic antitumour effect RC48 programmed cell death protein 1 (PD-1) inhibitors. We aimed evaluate safety plus toripalimab in...
Patients with recurrent or metastatic neuroendocrine neoplasms (NEN) had a poor prognosis and few treatment options. Toripalimab, humanized IgG4 antibody specific for human PD-1 receptor, was first approved to treat second-line melanoma in China 2018.The multiple-center phase Ib trial enrolled patients NENs (Ki-67 ≥ 10%) after failure of first-line therapy received 3 mg/kg toripalimab once every two weeks. The primary objective response rate (ORR) safety. PD-L1 expression whole-exome...
Hepatoid adenocarcinoma of the stomach (HAS) is characterized by histological resemblance to hepatocellular carcinoma and a poor prognosis. The aim this study elucidate clinicopathological molecular characteristics HAS.Forty-two patients with HAS who received gastrectomy were enrolled in study. Based on panel 483 cancer-related genes, targeted sequencing 24 22 clinical parameter-matched common gastric cancer (CGC) samples was performed. Prognostic factors for overall survival (OS)...
Despite the encouraging efficacy of anti-PD-1/PD-L1 immunotherapy in microsatellite-instability-high/deficient mismatch repair (MSI-H/dMMR) advanced gastrointestinal cancer, many patients exhibit primary or acquired resistance. Using multi-omics approaches, we interrogate gut microbiome, blood metabolome, and cytokines/chemokines with MSI-H/dMMR cancer (N = 77) at baseline during treatment. We identify a number microbes (e.g., Porphyromonadaceae) metabolites arginine) highly associated...
CT041 is a chimeric antigen receptor (CAR)-modified T-cell therapy that specifically targets claudin18.2 in solid tumors. Here, we report the pooled analysis results of two exploratory clinical trials to evaluate patients with previously treated pancreatic cancer (PC).
Abstract Background Dual inhibition of PD-1/PD-L1 and TGF-β pathways is a rational therapeutic strategy for malignancies. SHR-1701 new bifunctional fusion protein composed monoclonal antibody against PD-L1 fused with the extracellular domain receptor II. This first-in-human trial aimed to assess in pretreated advanced solid tumors find population who could benefit from SHR-1701. Methods was dose-escalation, dose-expansion, clinical-expansion phase 1 study. Dose escalation initiated by...
Background and Aims: We evaluated the efficacy safety of antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 in pretreated advanced biliary tract cancers (BTCs). Approach Results: In this pooled analysis two single‐center, phase Ib clinical trials (TQB2450‐Ib‐05 TQB2450‐Ib‐08 trials), 66 patients with BTCs who had progressed or declined were ineligible for first‐line chemotherapy included. With treatment achieved complete response, 12 partial response...
Abstract Approximately 50% of colorectal cancer (CRC) patients would develop metastasis with poor prognosis, therefore, it is necessary to effectively predict in clinical treatment. In this study, we aimed establish a machine-learning model for predicting CRC by considering radiomics and transcriptomics simultaneously. Here, 1023 from three centers were collected divided into five queues (Dazhou Central Hospital n = 517, Nanchong 120 the Cancer Genome Atlas (TCGA) 386). A total 854 features...
Background Platinum‐based chemotherapy is recommended for the treatment of advanced gastroenteropancreatic neuroendocrine carcinoma (GEP‐NEC). The objective current phase 2 study was to compare efficacy and toxicity between etoposide cisplatin (EP) irinotecan (IP) as first‐line in patients with GEP‐NEC. Methods Patients advanced, poorly differentiated GEP‐NEC randomly were assigned receive EP or IP. primary endpoint response rate (ORR). secondary endpoints progression‐free survival, overall...
Nimotuzumab (N) is a humanized anti-epidermal growth factor receptor monoclonal antibody. This prospective, single-armed, open label phase II study was conducted to evaluate the efficacy and safety of combination paclitaxel (T)/cisplatin (P) with nimotuzumab as first-line treatment in advanced esophageal squamous cell carcinoma (ESCC). Patients pathologic confirmed unresectable locally or metastatic ESCC were treated TPN regimen: 200 mg weekly, 175 mg/m(2) on day 1 cisplatin 30 days 2;...
Abstract Purpose This phase 1 trial evaluated the safety, preliminary efficacy, and pharmacokinetics of surufatinib, a small molecular tyrosine kinase inhibitor, combined with toripalimab, programmed cell death protein-1 antibody, in patients advanced solid tumors. Methods is an open-label, dose-escalation expansion study tumors who had failed standard therapies or no effective treatment. In stage, were treated at dose levels 200, 250, 300 mg once daily (QD) combination toripalimab 240 mg,...
Flux avalanches, prevalently existing in superconducting thin films, can cause catastrophic breakdowns of electromagnetic properties and even irreversible damage to materials. Metal coating is an effective way suppress the flux avalanches films. Nevertheless, it difficult reveal suppression mechanisms due challenge effectively separating simultaneous eddy currents heat exchange metal coating. In this work, Ag are separated by setting a thermal insulation layer, its inhibiting effect on YBCO...
<h3>Importance</h3> There are a limited number of predictive biomarkers for hyperprogressive disease (HPD), which is induced by immune checkpoint blockade (ICB) therapy. <h3>Objective</h3> To evaluate the association in serum with response to ICB therapy patients metastatic gastrointestinal tract cancer. <h3>Design, Setting, and Participants</h3> Cohort study cancer treated were enrolled at Department Gastrointestinal Oncology, Peking University Cancer Hospital Institute, Beijing, China,...
Abstract To explore the influence of pretreatment lymphopenia on toxicity and efficacy first‐line chemotherapy in patients with metastatic esophagus squamous cell carcinoma ( ESCC ). In total, 215 were included this retrospective study. Correlations between (lymphocyte count <1 × 10 9 /L) occurrence palliative investigated. Pretreatment was found 19.1% patients. The overall response rate ORR ) 35.5% (65 183 patients). Patients had a lower to compared those without (22.2% vs. 38.8%,...
IntroductionImmune checkpoint inhibitors (ICIs) have been approved for the late-line treatment of unresectable gastrointestinal tumors, but their efficacy and safety in neoadjuvant setting not described. Whether dMMR/MSI-H populations benefit from preoperative ICIs plus surgery remains undefined.Materials methodsSix consecutive patients managed at our institution received advanced, resectable, MSI-H tumors. All underwent thorough clinical evaluations radiographic investigations before during...
Abstract Objective Owing to its rarity and heterogeneity, the biological behavior optimal therapeutic management of mixed neuroendocrine‐non‐neuroendocrine neoplasm (MiNEN) have not been established. Herein, we aimed evaluate clinicopathological characteristics metastatic patterns MiNEN. Methods Continuous data MiNEN patients treated at our hospital were retrospectively collected analyzed. Results This study had enrolled 169 since January 2010 2020. Pathological components assessed in 129...